EP3981769A4 - Pyrrolopyrimidine compound and use thereof - Google Patents
Pyrrolopyrimidine compound and use thereof Download PDFInfo
- Publication number
- EP3981769A4 EP3981769A4 EP20817895.4A EP20817895A EP3981769A4 EP 3981769 A4 EP3981769 A4 EP 3981769A4 EP 20817895 A EP20817895 A EP 20817895A EP 3981769 A4 EP3981769 A4 EP 3981769A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pyrrolopyrimidine compound
- pyrrolopyrimidine
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Pyrrolopyrimidine compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910487056 | 2019-06-05 | ||
PCT/CN2020/094534 WO2020244614A1 (en) | 2019-06-05 | 2020-06-05 | Pyrrolopyrimidine compound and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3981769A1 EP3981769A1 (en) | 2022-04-13 |
EP3981769A4 true EP3981769A4 (en) | 2023-07-19 |
Family
ID=73653145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20817895.4A Pending EP3981769A4 (en) | 2019-06-05 | 2020-06-05 | Pyrrolopyrimidine compound and use thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220227788A1 (en) |
EP (1) | EP3981769A4 (en) |
JP (1) | JP7261428B2 (en) |
KR (1) | KR20220017995A (en) |
CN (1) | CN113939514B (en) |
AU (1) | AU2020288567B2 (en) |
CA (1) | CA3140467C (en) |
MX (1) | MX2021015056A (en) |
WO (1) | WO2020244614A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113372366B (en) * | 2020-12-04 | 2022-08-30 | 广州嘉越医药科技有限公司 | Salt of pyrrolopyrimidine compound, crystal form and application thereof |
CN114591333B (en) * | 2020-12-04 | 2023-08-01 | 广州嘉越医药科技有限公司 | Preparation method of pyrrolopyrimidine compound |
CN115124526B (en) * | 2020-12-04 | 2024-01-30 | 广州嘉越医药科技有限公司 | Pyrrolo pyrimidine compound intermediate and preparation method thereof |
WO2022242768A1 (en) * | 2021-05-21 | 2022-11-24 | 广州嘉越医药科技有限公司 | Use of pyrrolopyrimidine compound |
CN117295739A (en) * | 2021-05-26 | 2023-12-26 | 正大天晴药业集团股份有限公司 | Crystal and salt of tri-heterocyclic compound and application thereof |
CN114432317A (en) * | 2021-05-31 | 2022-05-06 | 广州嘉越医药科技有限公司 | Application of pyrrolopyrimidine compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013085802A1 (en) * | 2011-12-06 | 2013-06-13 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001042246A2 (en) * | 1999-12-10 | 2001-06-14 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
EP2563125A4 (en) * | 2010-04-27 | 2013-10-02 | Merck Sharp & Dohme | Azaindoles as janus kinase inhibitors |
WO2013088257A1 (en) * | 2011-12-12 | 2013-06-20 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors |
UA118149C2 (en) * | 2015-01-20 | 2018-11-26 | Вуксі Фортуне Фармасьютікал Ко., Лтд | Jak inhibitor |
PL3305788T3 (en) * | 2015-05-29 | 2021-03-08 | Wuxi Fortune Pharmaceutical Co., Ltd | Janus kinase inhibitor |
JP2018199623A (en) * | 2015-10-22 | 2018-12-20 | 大正製薬株式会社 | Nitrogen-containing condensation heterocyclic compound |
CN107652308A (en) * | 2017-10-31 | 2018-02-02 | 无锡福祈制药有限公司 | A kind of JAK3 inhibitor |
CN107805259A (en) * | 2017-10-31 | 2018-03-16 | 无锡福祈制药有限公司 | A kind of azolopyrimidines |
-
2020
- 2020-06-05 KR KR1020227000127A patent/KR20220017995A/en not_active Application Discontinuation
- 2020-06-05 EP EP20817895.4A patent/EP3981769A4/en active Pending
- 2020-06-05 CA CA3140467A patent/CA3140467C/en active Active
- 2020-06-05 CN CN202080040813.7A patent/CN113939514B/en active Active
- 2020-06-05 JP JP2021571814A patent/JP7261428B2/en active Active
- 2020-06-05 MX MX2021015056A patent/MX2021015056A/en unknown
- 2020-06-05 WO PCT/CN2020/094534 patent/WO2020244614A1/en unknown
- 2020-06-05 US US17/596,151 patent/US20220227788A1/en active Pending
- 2020-06-05 AU AU2020288567A patent/AU2020288567B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013085802A1 (en) * | 2011-12-06 | 2013-06-13 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
Non-Patent Citations (3)
Title |
---|
DATABASE Chemcats [online] 7 February 2012 (2012-02-07), AURORA BUILDING BLOCKS 7: "N-(5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-f]pyridin- 6-yl)-7H-pyrrolo[3,2-e]pyrimidin-4-amine", XP093052109, Database accession no. 1049145028 * |
DATABASE Chemcats [online] 7 June 2012 (2012-06-07), AURORA BUILDING BLOCKS 7: "[1,2,4]Triazolo[1,5-a]pyridin-6-amine, 5,6,7,8-tetrahydro-2-(1-methylethyl)-N-7H-pyrrolo[2,3-d]pyrimidin-4-yl-", XP093052105, Database accession no. 189747164 * |
See also references of WO2020244614A1 * |
Also Published As
Publication number | Publication date |
---|---|
MX2021015056A (en) | 2022-01-18 |
EP3981769A1 (en) | 2022-04-13 |
AU2020288567A1 (en) | 2022-02-03 |
KR20220017995A (en) | 2022-02-14 |
US20220227788A1 (en) | 2022-07-21 |
AU2020288567B2 (en) | 2023-06-15 |
JP7261428B2 (en) | 2023-04-20 |
CA3140467A1 (en) | 2020-12-10 |
CN113939514B (en) | 2022-12-27 |
CA3140467C (en) | 2023-08-01 |
CN113939514A (en) | 2022-01-14 |
JP2022535838A (en) | 2022-08-10 |
AU2020288567A8 (en) | 2023-02-09 |
WO2020244614A1 (en) | 2020-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3917934A4 (en) | Compounds and uses thereof | |
EP3917526A4 (en) | Compounds and uses thereof | |
EP3917529A4 (en) | Compounds and uses thereof | |
EP3746124A4 (en) | Compounds and uses thereof | |
EP3917517A4 (en) | Compounds and uses thereof | |
EP4050006A4 (en) | Bicyclic compound and use thereof | |
EP3849983A4 (en) | Triazolo-pyrimidine compounds and uses thereof | |
EP3981769A4 (en) | Pyrrolopyrimidine compound and use thereof | |
EP3992291A4 (en) | Novel compound and application thereof | |
EP3782998A4 (en) | Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof | |
EP3838900A4 (en) | 3-aryloxy-3-aryl-propylamine compound and uses thereof | |
EP3917527A4 (en) | Compounds and uses thereof | |
EP3760632A4 (en) | Pyrazolopyrimidine derivative and use thereof | |
EP3919498A4 (en) | Pyrrolopyrimidine derivative and use thereof | |
EP3892621A4 (en) | Haloallylamine compounds and application thereof | |
EP3941908A4 (en) | Compounds and uses thereof | |
EP3998254A4 (en) | 2-aminopyrimidine compound and application thereof | |
EP3853216A4 (en) | Substituted-pyridinyl compounds and uses thereof | |
EP3768269A4 (en) | Compounds and uses thereof | |
EP4034535A4 (en) | Aza-quinoline compounds and uses thereof | |
EP3911322A4 (en) | Compounds and uses thereof | |
EP3842441A4 (en) | Novel magnesium-serinate compound and use thereof | |
EP3914593A4 (en) | Compounds and uses thereof | |
EP4011898A4 (en) | 3-hydroxy-5-pregnane-20-one derivative and use thereof | |
EP3901146A4 (en) | Phenylpyrrolidine compound and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20211231 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40068570 Country of ref document: HK |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: C07D0487040000 Ipc: C07D0519000000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20230620 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/519 20060101ALI20230614BHEP Ipc: A61P 29/00 20060101ALI20230614BHEP Ipc: C07D 519/00 20060101AFI20230614BHEP |